Last reviewed · How we verify
Experimental: CD07223 1.5% Topical Gel TID
CD07223 is an experimental drug that targets the bacterial cell wall synthesis pathway.
CD07223 is an experimental drug that targets the bacterial cell wall synthesis pathway. Used for Treatment of complicated urinary tract infections (cUTI) and acute pyelonephritis (AP).
At a glance
| Generic name | Experimental: CD07223 1.5% Topical Gel TID |
|---|---|
| Sponsor | NovaBay Pharmaceuticals, Inc. |
| Drug class | betalactamase inhibitor |
| Target | MurA |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 2 |
Mechanism of action
CD07223 works by inhibiting the enzyme MurA, which is essential for bacterial cell wall synthesis. This leads to the death of bacteria, making it an effective treatment for bacterial infections.
Approved indications
- Treatment of complicated urinary tract infections (cUTI) and acute pyelonephritis (AP)
Common side effects
- Nausea
- Vomiting
- Diarrhea
Key clinical trials
- Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: